Initial Focus on MEAI ClinicalTrial Protocol
TORONTO,Aug. 3, 2021 -- Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the"Company"), a psychedelic medicine biotech company focused onthe discovery and development of novel psychedelic-derived therapeutics tosolve widespread and undertreated health problems, announces that Mark Hadenhas joined the Company’s Scientific Advisory Board (the “SAB”). The SAB’sinitial focus will be providing guidance on the Company’s request for anInvestigational New Drug review from the US Food and Drug Administration (“FDA”)for MEAI, for treating Alcohol Use Disorder (“AUD”).
Arecognized leader in the field, Mr. Haden has spent his career working toadvance the use of psychedelics in medicine. He currently serves as director ofclinical research at Psygen Industries, a manufacturer of pharmaceutical-gradepsychedelic drug products for clinical research and therapeutic applicationsand is an adjunct professor at the University of British Columbia School ofPopulation and Public Health.
Mr.Haden has substantial research experience, including a leadership role in thePRIME study (Psilocybin Research Investigating Medical Efficacy), whichexplores psilocybin as an adjunct in the treatment of substance use disorders,and he has spent 10 years as the chairman and executive director of MAPS Canada(Multidisciplinary Association for Psychedelic Studies), an organization hefounded. He has also dedicated over 25 years to working directly with patientsthrough the Vancouver Coastal Health Addiction Services at the Pacific SpiritCommunity Health Centre.
Heis a frequent keynote speaker on the topic of psychedelics and has beenpublished in a number of journals, including the Canadian Journal of PublicHealth, International Journal of Drug Policy, Encyclopedia of Public Health,Harm Reduction Journal, Open Medicine, Journal of Psychoactive Drugs, and theJournal of Studies on Alcohol and Drugs. He was also instrumental in helpingthe Health Officers Council of British Columbia develop their position papers,lectures and presentations on issues regarding the regulation of illegal drugs.
“Markis an important addition to our SAB. He is one of the world’s leading advocatesfor the legalization of psychedelics and a strong proponent of their medicinalvalue. His research into psychedelics and their potential to treat addictionparallels the work we are doing to develop therapies to manage AUD, and I amconfident that his contribution to our efforts to secure FDA approval for MEAI willbe invaluable,” commented Adi Zuloff-Shani, Ph.D., CEO of Clearmind.
Mr.Haden noted, “Clearmind’s innovative approach to harnessing the propertiesof psychedelics to create therapeutics for mental health issues has thepotential to change millions of lives around the world. I have spent my careeron a similar quest, and I am delighted to facilitate this effort in any way Ican. I very much look forward to working with the talented team at Clearmind aswell as the other distinguished members of the advisory board.”
AboutClearmind Medicine Inc.
Clearmindis a psychedelic pharmaceutical biotech company focused on the discovery anddevelopment of novel psychedelic-derived therapeutics to solve widespread and underservedhealth problems, including alcohol use disorder. Its primary objective is to researchand develop psychedelic-based compounds and attempt to commercialize them asregulated medicines, foods or supplements.
TheCompany’s intellectual portfolio currently consists of two patent families. Thefirst, "Binge Behavior Regulators", has been granted in the U.S.,Europe, China and India, with pending divisional applications in Europe and theU.S. The second, “Alcohol Beverage Substitute”, has been approved for aEuropean patent, with pending applications in the U.S., China and India. TheCompany intends to seek additional patents for its compounds whenever warrantedand will remain opportunistic regarding the acquisition of additional intellectualproperty to build its portfolio.
Sharesof Clearmind are listed for trading on the Canadian Securities Exchange underthe symbol "CMND."
For further information, please contact:
Investor Relations,
Email:invest@clearmindmedicine.com
Telephone: (778) 400-5347
General Inquiries,
FORWARD-LOOKING STATEMENTS:
Thisnews release may contain forward-looking statements and information based oncurrent expectations. These statements should not be read as guarantees offuture performance or results. Such statements involve known and unknown risks,uncertainties and other factors that may cause actual results, performance orachievements to be materially different from those implied by such statements.Such statements include submission of the relevant documentation within therequired timeframe to the satisfaction of the relevant regulators and raisingsufficient financing to complete the Company's business strategy. There is nocertainty that any of these events will occur. Although such statements arebased on management's reasonable assumptions, there can be no assurance thatsuch assumptions will prove to be correct. We assume no responsibility toupdate or revise them to reflect new events or circumstances.
Investinginto early-stage companies inherently carries a high degree of risk, andinvestment into securities of the Company shall be considered highlyspeculative.
Thispress release shall not constitute an offer to sell or the solicitation of anoffer to buy, nor shall there be any sale of the securities in any province inwhich such offer, solicitation or sale would be unlawful.
Neitherthe Canadian Securities Exchange (the “CSE”) nor its Regulation ServicesProvider (as that term is defined in the policies of the CSE) acceptsresponsibility for the adequacy or accuracy of this release.
